Citigroup’s ZyVersa Therapeutics ZVSA Stock Holding History

Citigroup’s Portfolio ZVSA Stock Details ZVSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-274	Closed	-$186	–	6354
2025 Q2	$186	Buy	+274	New	+$179	﹤0.01%	5487
2025 Q1	–	Sell	-35,035	Closed	-$37.1K	–	6030
2024 Q4	$37.1K	Buy	+35,035	New	+$55.3K	﹤0.01%	5151

Other funds holding ZVSA

Guerra Advisors Miami, Florida $271M AUM 27.78% 1-Year Est. Return

Citigroup's ZVSA Position: Q3 2025 in Review

Citigroup sold out of ZyVersa Therapeutics (ZVSA) in Q3 2025, closing a stake of 274 shares — an estimated $186 sold.

Citigroup first reported a position in ZVSA in Q4 2024 and held it in 2 quarters. The position peaked at $37.1K in Q4 2024. 1 fund tracked by Wall St. Rank holds ZVSA as of Q3 2025.

Citigroup reported no remaining ZyVersa Therapeutics position as of Q3 2025 after selling out during the quarter.
Citigroup sold 274 ZyVersa Therapeutics shares in Q3 2025, an estimated $186.
Citigroup first reported a position in ZyVersa Therapeutics in Q4 2024 and held it in 2 quarters.
Citigroup's ZyVersa Therapeutics position peaked at $37.1K in Q4 2024.
1 fund tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.